Grace Therapeutics earnings were -$10.3M for the trailing 12 months ending Jun 30, 2025, with N/A growth year over year. The latest GRCE earnings report on Jun 30, 2025 announced Q2 2025 earnings of -$3.4M, down 628.6% from last quarter. For the last reported fiscal year 2025 ending Mar 31, 2025, GRCE reported annual earnings of -$9.6M, with -25.6% growth.
What were Grace Therapeutics's earnings last quarter?
Grace Therapeutics (NASDAQ: GRCE) reported Q2 2025 earnings per share (EPS) of -$0.21, up 12.5% year over year. Total GRCE earnings for the quarter were -$3.36 million. In the same quarter last year, Grace Therapeutics's earnings per share (EPS) was -$0.24.
As of the last Grace Therapeutics earnings report, Grace Therapeutics is currently losing money. Grace Therapeutics's net profit (also called net income) for the twelve months ending Jun 30, 2025 was -$10.31 million, a 9.91% decrease year over year.
What was GRCE's earnings growth in the past year?
As of Grace Therapeutics's earnings date in Q3 2025, Grace Therapeutics's earnings has grown year over year. GRCE earnings in the past year totalled -$10.31 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.